Group items matching

in title, tags, annotations or url

Is Diet More Important Than Exercising? http://t.co/aLlDzwHccx While there are many common myths and questions surrounding weight loss and fitness, it seems whenever you go to a gym you will hear people asking is diet more important than exercise or is it the other way around. Today we will help you to get the the bottom of this conundrum and improve your own fitness results in the process. Depending upon who you ask and their own fitness background, it's highly likely that you will get a different answer every time you pose this question to somebody. Ultimately, many of us base our decision purely off our own experiences and opinions. For instance, everybody has a friend who is always trying to latest celebrity diet plan. That friend will probably put huge faith in their eating plan being the most important factor because it's what they know.

With 62% of women admitting in a recent British survey (Daily Mail) that they plan to slim down for the festive season, November has been earmarked as the time to start in order to safely drop a dress size. So let's see how scientific reaserch can help us getting fit choosing the right diet plan...

Fatty Liver Diet Plan Blog

Google plans to change the model of internet communication,by releasing the GOOGLE WAVE.Google wave is planned to be released in later part of this year.

Find a diet plan to lose weight fast and start on your journey to a healthier you. You can look better and feel great with a few simple steps designed with you in mind. Check out what is available today.

Joint pain treatment plans include various ways to manage pain and improve the overall function of the body. No mode of management in isolation can be termed as the best joint pain remedy it's the combination of plans which work out to yield a significant result.

What is The 21 Day Flat Belly Fix Recipe? Using the simplest words possible, the flat belly fix program is a weight loss manual by Todd Lamb intended to set you on the right path to eliminating your stubborn belly fat without starving yourself or doing any exercise more strenuous than walking to the fridge. The flat belly fix diet book focuses on a simple to follow step-by-step guides to help almost anyone naturally get rid of their excess belly fat rather than the heavy workout, weight loss pills and surgical approach that are expensive and not a safe way to lose body fat. The flat belly fix is not just a pack of diet plans that will help you shed excess body fat, it includes interesting and easy to carry out workout plans, and it is accompanied with weekly one-on-one ...click link for more

Keto Can Control Your Diabetes Risk By 60% Best keto Diet Plan Keto Diet Can Cut You Diabetes Risk Best keto Diet Plan

The Royal Pharmaceutical Society (RPS) has welcomed the Health Secretary Sajid Javid's plan to appoint Hormone Replacement Therapy (HRT) tsar to tackle the medicine shortages. On Sunday (April 24) Sajid Javid told the Mail that he planned to tackle the problem (shortage of HRT medicine) by appointing a new HRT tsar with the role modelled on that of Kate Bingham, who successfully led the government's Covid vaccine taskforce. "The difficulties in accessing HRT medicine have unfairly impacted women's mental health," said RPS President, Professor Claire Anderson. "I look forward to working with this new champion for HRT and the Government on how we can better support women's health, building on the positive move to reduce prescription charges for HRT for women." Anderson also stressed that "the Government should now go further and end unfair prescription charges for patients in England altogether."

Maxwellia has revealed its plans to switch some of its medicines in the self-care category from prescription-only-medicine (POM) to a pharmacy (P) medicine. After authorising the switch of Maxwellia's two brands of desogestrel contraceptive pills, Lovima and Hana, MHRA has opened a public consultation on reclassification of Aquiette (overactive bladder treatment) 2.5mg tablets manufactured by the company to be made available from pharmacies. "Maxwellia is currently looking at a number of medicines which treat a range of conditions in major public health categories that can be 'switched' from needing a prescription to being conveniently bought at a local high street or supermarket pharmacy. With its foot firmly on the accelerator it has other applications under assessment with the MHRA, including women's health products," the company stated in a recent statement. "Push to convert more prescription medicines to pharmacy medicines will firmly position pharmacists at heart of nation's public health, helping futureproof NHS," the medicine said.

Consumer goods giant Unilever signalled on Monday (January 17) it would pursue a deal for GlaxoSmithKline's consumer healthcare business, calling it a "strong strategic fit" after its £50 billion offer was refused. GSK confirmed on Saturday that it had rejected three approaches from the Dove-soap maker, adding it intended to stick to its own plan to spin off the business as a separate company later this year. "GSK Consumer Healthcare would be a strong strategic fit," Unilever said in a statement as it unveiled a strategy update in the wake of the weekend's takeover news. Unilever said it was "committed to accelerating the company's growth and repositioning the portfolio into higher growth categories. "As a result of the reporting of Unilever's interest in GSK Consumer Healthcare, we are today bringing forward a planned update, setting out the strategic direction that the company is pursuing," Unilever said.

To increase efficiency savings, digital men's health provider Numan has joined forces with Invatech Health to deploy the health tech company's cutting-edge software Titan. Launched in early 2019, Numan provides medication for 175,000 patients via its Cardiff-based fulfilment operation. A team of its clinicians create personalised treatment plans for the most common male health concerns. In a statement, Invatech said its Titan software could deliver 20 per cent efficiency savings for Numan whilst supporting the company's ambitious growth plans with improved safety and scalability in processing medications. The new partnership also comes alongside 100 new contracts with community pharmacies around the UK. Andrew Caple, director of Pharmacy Operations at of Numan, said: "Our findings show that three quarters of men will not visit a doctor when they have a health concern, and we therefore recognise that the online market provides a great opportunity to tackle these problems.

Centre for Pharmacy PostGraduate Education (CPPE) has announced the launch of a new learning programme, Preparing to train as an independent prescriber. The programme aims to build the confidence and competence of pharmacists who are planning to apply and train as independent prescribers and is open to pharmacists from all sectors of practice, including community pharmacists who are planning to commence their independent prescriber training with a Higher Education Institute (HEI). The course is made up of four main components, including a self-directed e-course and self-assessment framework, a mandatory online workshop to support you to review your self-assessment of competencies, an optional online workshop to support your readiness for academic writing and reflective practice, and optional peer support sessions, providing the opportunity for you to develop your professional network and establish communities of practice.

As part of efforts to streamline spending and enhance resource allocation within the healthcare system, the NHS has chosen to cease providing the free vaccinations for all, which were initially introduced in 2020. Approximately 12 million British citizens will not have access to free flu vaccinations and Covid-19 boosters during the upcoming winter, according to NHS. Furthermore, the NHS plans to defer flu vaccine distribution to October, aiming to heighten protection for those aged 65 and older and other eligible groups in the high-risk winter months. However, this has stirred panic among pharmacies, given their advanced planning based on the initial start date of September 1 for vaccinations. On Tuesday (Aug. 8), the Joint Committee on Vaccination and Immunisation (JCVI) released NHS guidelines indicating that Covid-19 booster shots, starting from autumn, will not be provided to individuals aged 50 to 64 who are in otherwise good health. Similar guidance had already been released for flu, rendering 12 million middle-aged Britons ineligible for free jabs, JCVI said. Prior to the pandemic, influenza vaccinations were available to healthy adults aged over 65, alongside children and younger adults with medical conditions. Amidst the pandemic, the distribution of flu vaccinations was expanded to include individuals aged 50 to 64, in alignment with the criteria for Covid-19 boosters.

Has the government in England learned nothing from the Covid-19 pandemic? Nigel Swift, Managing Director of Rowlands Pharmacy, part of Numark, the UK's largest pharmacy membership association, asks reflecting on the disorderly launch of this year's flu and Covid booster vaccination program as evidence to the contrary. "Community pharmacies play a crucial role in ensuring eligible individuals can easily access their free NHS flu and Covid vaccinations," Swift said, adding that delivering this essential service necessitates pharmacy staff allocating time for preparation and appointment scheduling. "Just a few weeks ago, NHSE informed us that the vaccination program would be postponed until October, prompting pharmacies to plan accordingly and notify patients," he said. "However, NHSE has now reversed its decision and set the program to commence on Sept. 11. Pharmacy recommended an earlier start, but NHSE opted for a delay instead, resulting in avoidable problems." On Aug. 30, NHSE announced plans to move up the start of the autumn vaccination drive in England to September 11, deviating from the initial October schedule, citing concerns about a new Covid-19 variant.

The NHS has launched plans to expand pioneering subscription-style drug contracts to develop lifesaving antibiotics of the future. It is building on its world-first pilot to incentivise the pharmaceutical industry to develop new antibiotics that could be offered to NHS patients when they need them the most. The consultation has launched almost a year to the day that contracts for two superbug-busting drugs were rolled out as part of a world-first pilot. Cefiderocol and ceftazidime-avibactam, new antibiotics manufactured by Shionogi and Pfizer respectively, were awarded world-first subscription contracts which provided the companies with a fixed annual fee based primarily on the availability of the drugs and their value to the NHS, as opposed to the volumes used. By breaking the link between the payments companies receive and the number of their antibiotics prescribed, the NHS is removing any incentive to overuse antibiotics, decreasing the risk of life-threatening infections, such as sepsis and pneumonia, becoming resistant to treatment.

The pharmacy inquiry will explore issues impacting different types of pharmacy, with a particular focus on community, primary care and hospital pharmacy services. It will also consider current challenges around funding, workforce and the digital infrastructure. Planned developments within the profession will enable future pharmacists to be independent prescribers from day one of registration, giving them a greater role within primary care teams. Health and Social Care Committee Chair Steve Brine MP said: "It is clear that pharmacy has a central role to play in the future of the NHS. With a greater focus on personalised and patient-centred healthcare, we will be asking what more must be done to make sure that the profession is in the best shape to meet demand. "Better use of the pharmacy workforce would reduce pressures on general practice and hospitals. However, this will not happen without a planned workforce with the funding, supervision and training to support it. "At the end of the inquiry, the committee will be making recommendations to the government on what action needs to be taken to ensure the potential of pharmacy is realised.

British pharmacy chain Superdrug has announced plans to cease the sale of disposable vapes in all its UK and Ireland stores, citing the environmental impact caused by its disposal and popularity among young people. The pharmacy retailer will discontinue selling brands like Vuse GO and Flavaah Bars, with plans to completely clear out existing stock by the end of the year, the company said in statement. Superdrug, which previously sold 1,300 single-use vapes weekly, expects a potential impact on revenue stemming from this decision. The company has not yet started selling vapes online. "This decision was made to safeguard the environment," the company said on Sept.22, highlighting the risk of fires due to improper disposal of vapes, as many of them contain lithium batteries.

The Joint Committee on Vaccination and Immunisation (JCVI) has advised booster vaccination to be offered this autumn (2023) for those at higher risk of severe Covid-19 in its interim advice to government on the coronavirus (COVID-19) vaccination programme for 2023. The JCVI also advised that for a smaller group of people, such as those who are older and those who are immunosuppressed, an extra booster vaccine dose in the spring should also be planned for. Professor Wei Shen Lim, Chair of Covid-19 vaccination on the JCVI, said: "The Covid-19 vaccination programme continues to reduce severe disease across the population, while helping to protect the NHS. That is why we have advised planning for further booster vaccines for persons at higher risk of serious illness through an autumn booster programme later this year. We will very shortly also provide final advice on a spring booster programme for those at greatest risk."

Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year. It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost. One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000 per year. "Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer. Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain swelling and brain bleeding.